(-) Erythro α-Methyl Epinephrine for Cerebral Blood Flow
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cerebral and ocular ischemia associated with diseases like Alzheimer's, macular degeneration, and retinopathy of diabetes fail to effectively enhance blood flow and restore vascular autoregulation, leading to continued vision and memory loss.
Innovation Solution
Administration of an aqueous composition containing the (-) erythro isomer of α-methyl epinephrine or α-methyl norepinephrine, which increases cerebral and ocular blood flow by at least 5% through various routes such as topical, oral, buccal, or intravenous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for cerebral and ocular ischemia, then other disease symptoms may be managed, but blood flow enhancement and vascular autoregulation restoration fail to occur effectively
Solution Approach 1:
The patent changes the chemical parameter by using a specific enantiomer (levorotatory isomer) of catecholamine compounds rather than conventional treatments. This parameter change in molecular configuration enables selective activation of vascular autoregulation mechanisms, thereby effectively enhancing blood flow to cerebral and ocular tissues where conventional treatments fail.
2Quantity of substance
If blood flow is increased to enhance oxygen delivery, then ischemia symptoms improve, but vascular autoregulation capacity is not restored
Solution Approach 1:
The patent employs a feedback mechanism where the levorotatory catecholamine enantiomer activates alpha-adrenergic receptors on vascular smooth muscle cells, triggering a reflex response that restores vascular autoregulation. This feedback loop enables the vascular system to self-regulate blood flow distribution, not merely increase overall flow volume, thereby addressing both blood flow quantity and autoregulation stability.
3Reliability
If enantiomer selection is made to improve therapeutic efficacy, then blood flow enhancement is achieved, but treatment complexity increases
Solution Approach 1:
The patent extracts and isolates only the therapeutically active levorotatory enantiomer from the racemic mixture of catecholamines. By taking out only the effective (-) isomer and excluding the inactive or potentially harmful (+) isomer, the treatment achieves superior therapeutic efficacy while simplifying the pharmaceutical formulation and reducing dosing complexity compared to using conventional racemic mixtures.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Ocular and cerebral blood flow are enhanced by the administration of (-) erythro isomer of a-methyl epinephrine, a C1 to C8 aliphatic ester of a-methyl epinephrine, a-methyl norepinephrine, a C1 to C8 aliphatic ester of a-methyl norepinephrine, or a pharmacologically acceptable acid addition salt thereof.